30/09/2026 Roche’s fenebrutinib received US FDA filing acceptance for RMS and PPMS Merck’s tulisokibart met primary and key secondary endpoints in Ph2b HS study Roche’s fenebrutinib received US FDA filing acceptance for RMS and PPMS (Ref) The US FDA accepted Roche’s NDA for fenebrutinib (BTKi) under Priority Review for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), supported by Ph3 FENhance 1 and 2 RMS studies and the Ph